BPC-157 vs GHK-Cu
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, BPC-157 or GHK-Cu?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between BPC-157 and GHK-Cu?
BPC-157 is primarily studied for systemic tissue repair (tendon, GI, bone) via injection; GHK-Cu is primarily validated for topical skin applications and has a completely different target profile.
Evidence Comparison
BPC-157: Level B with 70+ rodent studies but zero published human efficacy trials. GHK-Cu: Level B with multiple small human RCTs for skin applications (collagen synthesis, wrinkle reduction) and one of the few cosmetically-used peptides with human data. Both lack large-scale human RCTs.
Evidence Context Favoring BPC-157
Research contexts involving musculoskeletal injury, gut healing, or systemic anti-inflammatory effects.
Evidence Context Favoring GHK-Cu
Skin rejuvenation applications where topical human efficacy data matters; GHK-Cu has the more credible cosmetic evidence base.
Side-by-Side Snapshot
| Evidence grade | BPC-157: Level B GHK-Cu: Level B |
|---|---|
| Research status | BPC-157: Phase 2 GHK-Cu: Phase 2 |
| Primary category | BPC-157: Healing & Recovery GHK-Cu: Skin & Beauty |
| Cited studies | BPC-157: 10 GHK-Cu: 6 |